People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Other Health Care, Investment Vehicle, Pharma, Software / Tech, Healthtech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avicena North America Inc. | — | Other Health Care | Series C | $44.4M | $652.4M | 2022 |
| TCSPV Holdings IV, LLC | — | Investment Vehicle | Series A | $8.9M | $28.6M | 2025 |
| Colorado Therapeutics LLC | — | Pharma | Series A | $6.9M | $79.6M | 2015 |
| Great Lakes Crystal Technologies, Inc. | — | Software / Tech | Seed | $6.0M | $11.7M | 2023 |
| Attwill Vascular Technologies LP | — | Software / Tech | Seed | $5.4M | $29.6M | 2020 |
| Virtual Dental Care, Inc. | — | Healthtech | Seed | $3.2M | $87.4M | 2020 |
| Orthoevidence Inc. | — | Other Health Care | Pre-Seed | $1.1M | $30.8M | 2015 |
| Adventa Bioscience Inc. | — | Biotechnology | Pre-Seed | $410K | $7.9M | 2022 |
William Jackson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Jackson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Lee | 1 | 7 |
| John McKay | 1 | 5 |
| Ian Reynolds | 1 | 4 |
| Robert Geoffrey Browne | 1 | 2 |
| Jonathan Charak | 1 | 2 |
| James Gleason | 1 | 2 |
| Thomas Raegan | 1 | 1 |
| Vipul Sharma | 1 | 1 |
| James Gleeson | 1 | 1 |
| David Delfino | 1 | 1 |
| Keith Evans | 1 | 1 |
| Peter Greenwood | 1 | 1 |
| Andre Bobek | 1 | 1 |
| Stacy Klousiadis | 1 | 1 |
| Joseph Horn | 1 | 1 |
| Mustafa Chagal | 1 | 1 |
| Hari Radhakrishnan | 1 | 1 |
| Timothy Grotjohn | 1 | 1 |
| Eric Schabule | 1 | 1 |
| Gareth Tingling | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.